The MedSeq Project: a randomized trial of integrating whole genome sequencing into clinical medicine

Vassy, Lautenbach, McLaughlin, Kong, Christensen, Krier, Kohane, Feuerman, Blumenthal-Barby, Roberts, et al. The MedSeq Project: a randomized trial of integrating whole genome sequencing into clinical medicine. TrialsTrialsTrials. 2014;15:85.

NOTES

Vassy, Jason LLautenbach, Denise MMcLaughlin, Heather MKong, Sek WonChristensen, Kurt DKrier, JoelKohane, Isaac SFeuerman, Lindsay ZBlumenthal-Barby, JenniferRoberts, J ScottLehmann, Lisa SoleymaniHo, Carolyn YUbel, Peter AMacRae, Calum ASeidman, Christine EMurray, Michael FMcGuire, Amy LRehm, Heidi LGreen, Robert CengF32 HG006993/HG/NHGRI NIH HHS/L30 DK089597/DK/NIDDK NIH HHS/T32 GM007748-34/GM/NIGMS NIH HHS/U01 HG006500/HG/NHGRI NIH HHS/U01-HG006500/HG/NHGRI NIH HHS/UL1 RR025758/RR/NCRR NIH HHS/UL1RR025758/RR/NCRR NIH HHS/Comparative StudyRandomized Controlled TrialResearch Support, N.I.H., ExtramuralEngland2014/03/22 06:00Trials. 2014 Mar 20;15:85. doi: 10.1186/1745-6215-15-85.

Abstract

BACKGROUND: Whole genome sequencing (WGS) is already being used in certain clinical and research settings, but its impact on patient well-being, health-care utilization, and clinical decision-making remains largely unstudied. It is also unknown how best to communicate sequencing results to physicians and patients to improve health. We describe the design of the MedSeq Project: the first randomized trials of WGS in clinical care. METHODS/DESIGN: This pair of randomized controlled trials compares WGS to standard of care in two clinical contexts: (a) disease-specific genomic medicine in a cardiomyopathy clinic and (b) general genomic medicine in primary care. We are recruiting 8 to 12 cardiologists, 8 to 12 primary care physicians, and approximately 200 of their patients. Patient participants in both the cardiology and primary care trials are randomly assigned to receive a family history assessment with or without WGS. Our laboratory delivers a genome report to physician participants that balances the needs to enhance understandability of genomic information and to convey its complexity. We provide an educational curriculum for physician participants and offer them a hotline to genetics professionals for guidance in interpreting and managing their patients' genome reports. Using varied data sources, including surveys, semi-structured interviews, and review of clinical data, we measure the attitudes, behaviors and outcomes of physician and patient participants at multiple time points before and after the disclosure of these results. DISCUSSION: The impact of emerging sequencing technologies on patient care is unclear. We have designed a process of interpreting WGS results and delivering them to physicians in a way that anticipates how we envision genomic medicine will evolve in the near future. That is, our WGS report provides clinically relevant information while communicating the complexity and uncertainty of WGS results to physicians and, through physicians, to their patients. This project will not only illuminate the impact of integrating genomic medicine into the clinical care of patients but also inform the design of future studies. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT01736566.
Last updated on 02/25/2023